Buy & Sell Incyte Corporation (INCY) – Incyte Corporation Price Today
Key Stats
- $19.12BMarket Cap
- HealthSector
- -17.18%3M Drawdown
- $15.58BEnterprise Value
- -Dividend Yield
- 29 daysTypical Hold Time
Incyte Corporation (INCY) is currently valued at a market capitalization of $19.12B, with an enterprise value of $15.58B. Over the past 52 weeks, Incyte Corporation has traded between a low of $56.8 and a high of $110.57, highlighting its annual price range. Over the past three months, Incyte Corporation has recorded a drawdown of -17.18%, reflecting recent price volatility. Incyte Corporation offers a dividend yield of -. On average, investors hold Incyte Corporation for approximately 29 days, indicating typical investor behavior on the platform.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
